

2026 PULMONOLOGY SYMPOSIUM

Program Agenda:

7:15-7:45 am	Registration & Continental Breakfast
7:45-8 am	Welcome & Introduction Asaad Jandali, MD
8-8:45 am	Pulmonary Embolism Asaad Jandali, MD
8:45 – 9:30 am	Advancement Procedural Treatment for COPD Abdulrahman Katabi, MD
9:30 –9:45 am	Q&A
9:45-10 am	Break
10-10:45 am	Pleural Effusion Daniel F. Martin, MD
10:45-11:30 am	Pulmonary Ablation Beyond Thermal Techniques: Emerging Role of Pulsed Electric Field Ablation. Essam Mekhaiel, MD
11:30 am-12:15 pm	ESEN RAT-Revisiting Fleischner Guidelines Hasnain Bawaadam, MD Uzair Ghori, MD
12:15-12:30 pm	Q&A
12:30-12:55 pm	Luncheon
12:55-1:25 pm	Panel Discussion and Evaluations
1:30 pm	Adjournment

Accreditation:

Powers Health (PH) is accredited by the Indiana State Medical Association to provide continuing medical education for physicians.

Powers Health Community Hospital is approved as a provider of nursing continuing professional development by VTL Center for Professional Development, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. 4.75 contact hours awarded for completed registration form, attendance of the entire live activity, and completion of the evaluation. VTL Provider Approval Number: IN228-3.

CNE contact hours awarded for completed registration form, attendance of the entire live activity, and completion of the evaluation.

Designation:

Powers Health designates this live activity for a maximum of 4.75 AMA PRA Category 1 credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy:

In accordance with ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by the Powers Health must ensure balance, independence, objectivity, and scientific rigor in all sponsored educational programs. Prior to the activity, all faculty, authors, editors, and planners participating in a PH-sponsored activity are required to disclose to attendees any relevant financial relationship with an "ineligible company" whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Statement:

Asaad Jandali, MD and Abdulrahman A. Katabi, MD discloses no relevant financial relationship with any ineligible companies. Daniel F. Martin, MD discloses being a consultant for Intuitive Surgical, on the speaker's Bureau for Cornerstone Specialty Network, Grant/Research Support with MJH life Sciences; Uzair Ghori, discloses being a consultant for GLG, Guidepoint, Intuitive, Micro1 AI, Green Light AI. Hasnain Bawaadam, MD discloses being a consultant for Intuitive Surgical, on the Speaker's Bureau for Cook Medical, Siemens Healthineers, Biodesix, Circulogene and AstraZeneca. Essam Mekhaiel, MD discloses that he is Consultant for Glavanize, Siemens, Ambu and Cook Medical and on the Speakers Bureau for Glavanize, Siemens. These were discussed with the speakers and all relevant financial relationship has been mitigated and resolved. No other relevant financial relationship that were identified for any member of the planning committee or presenter/author. The CME/CNE Staff discloses no relevant relationship with any ineligible companies

Saturday, March 7

7:15 am-1:30 pm

Center for Visual and Performing Arts
1040 Ridge Road, Munster

REGISTRATION

This symposium is FREE; preregistration required by Tuesday, Feb. 24, 2026.

To register, please use the QR code or login to HealthStream account; catalog tab; 41119.

If you have any questions, email Aquilina Ritacca, Continuing Medical Education Coordinator, at aritacca@powershealth.org or call 219-703-1790.



SCAN TO REGISTER

Program Objectives:

1. Review pulmonary embolism.
2. Identify risk stratification.
3. Identify the role of interventional cardiologist, how can they help.
4. Discuss COPD procedural management.
5. Overview of current pulmonary ablation modalities.
6. Mechanism of action of pulsed electric field (PEF) ablation.
7. Current clinical data and future directions for PEF in pulmonary medicine.
8. Patient selection considerations for PEF ablation.
9. Defining the terms of pleural effusion.
10. Describe the pathophysiology of pleural effusion.
11. Evaluate prognosis of pleural effusion.
12. Explain management options.
13. Understand current Fleischner Guidelines.
14. Identify risk factors for biopsying sub 8mm nodules.
15. Developing a robust AI-based scoring tool and algorithm to identify which sub 8mm nodule should be biopsied.
16. Understand its overall applicability in the current landscape of robotic bronchoscopy with nuclear markers.